125 related articles for article (PubMed ID: 18156799)
1. Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas.
Faber AC; Chiles TC
Cell Cycle; 2007 Dec; 6(23):2982-9. PubMed ID: 18156799
[TBL] [Abstract][Full Text] [Related]
2. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.
MacCallum DE; Melville J; Frame S; Watt K; Anderson S; Gianella-Borradori A; Lane DP; Green SR
Cancer Res; 2005 Jun; 65(12):5399-407. PubMed ID: 15958589
[TBL] [Abstract][Full Text] [Related]
3. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism.
Gao N; Kramer L; Rahmani M; Dent P; Grant S
Mol Pharmacol; 2006 Aug; 70(2):645-55. PubMed ID: 16672643
[TBL] [Abstract][Full Text] [Related]
4. Cyclin D3 is dispensable for human diffuse large B-cell lymphoma survival and growth: evidence for redundancy with cyclin E.
Gumina MR; Xu C; Chiles TC
Cell Cycle; 2010 Feb; 9(4):820-8. PubMed ID: 20107311
[TBL] [Abstract][Full Text] [Related]
5. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.
Cai D; Byth KF; Shapiro GI
Cancer Res; 2006 Jan; 66(1):435-44. PubMed ID: 16397259
[TBL] [Abstract][Full Text] [Related]
6. Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.
Choudhary GS; Tat TT; Misra S; Hill BT; Smith MR; Almasan A; Mazumder S
Oncotarget; 2015 Jul; 6(19):16912-25. PubMed ID: 26219338
[TBL] [Abstract][Full Text] [Related]
7. Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation.
Baldassarre G; Barone MV; Belletti B; Sandomenico C; Bruni P; Spiezia S; Boccia A; Vento MT; Romano A; Pepe S; Fusco A; Viglietto G
Oncogene; 1999 Nov; 18(46):6241-51. PubMed ID: 10597222
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase C delta inhibits Caco-2 cell proliferation by selective changes in cell cycle and cell death regulators.
Cerda SR; Mustafi R; Little H; Cohen G; Khare S; Moore C; Majumder P; Bissonnette M
Oncogene; 2006 May; 25(22):3123-38. PubMed ID: 16434969
[TBL] [Abstract][Full Text] [Related]
9. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
Raje N; Kumar S; Hideshima T; Roccaro A; Ishitsuka K; Yasui H; Shiraishi N; Chauhan D; Munshi NC; Green SR; Anderson KC
Blood; 2005 Aug; 106(3):1042-7. PubMed ID: 15827128
[TBL] [Abstract][Full Text] [Related]
10. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
11. The cyclin-dependent kinase inhibitor R-roscovitine down-regulates Mcl-1 to override pro-inflammatory signalling and drive neutrophil apoptosis.
Leitch AE; Riley NA; Sheldrake TA; Festa M; Fox S; Duffin R; Haslett C; Rossi AG
Eur J Immunol; 2010 Apr; 40(4):1127-38. PubMed ID: 20127676
[TBL] [Abstract][Full Text] [Related]
12. The fate of pancreatic tumor cell lines following p16 overexpression depends on the modulation of CDK2 activity.
Calbó J; Serna C; Garriga J; Graña X; Mazo A
Cell Death Differ; 2004 Oct; 11(10):1055-65. PubMed ID: 15309028
[TBL] [Abstract][Full Text] [Related]
13. DNA damaging agent-induced apoptosis is regulated by MCL-1 phosphorylation and degradation mediated by the Noxa/MCL-1/CDK2 complex.
Nakajima W; Sharma K; Lee JY; Maxim NT; Hicks MA; Vu TT; Luu A; Yeudall WA; Tanaka N; Harada H
Oncotarget; 2016 Jun; 7(24):36353-36365. PubMed ID: 27166195
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
Rosato RR; Almenara JA; Maggio SC; Atadja P; Craig R; Vrana J; Dent P; Grant S
Mol Cancer Ther; 2005 Nov; 4(11):1772-85. PubMed ID: 16275999
[TBL] [Abstract][Full Text] [Related]
15. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.
Cai D; Latham VM; Zhang X; Shapiro GI
Cancer Res; 2006 Sep; 66(18):9270-80. PubMed ID: 16982772
[TBL] [Abstract][Full Text] [Related]
16. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
Dey J; Deckwerth TL; Kerwin WS; Casalini JR; Merrell AJ; Grenley MO; Burns C; Ditzler SH; Dixon CP; Beirne E; Gillespie KC; Kleinman EF; Klinghoffer RA
Sci Rep; 2017 Dec; 7(1):18007. PubMed ID: 29269870
[TBL] [Abstract][Full Text] [Related]
17. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
18. Depletion of SUMO ligase hMMS21 impairs G1 to S transition in MCF-7 breast cancer cells.
Ni HJ; Chang YN; Kao PH; Chai SP; Hsieh YH; Wang DH; Fong JC
Biochim Biophys Acta; 2012 Dec; 1820(12):1893-900. PubMed ID: 22906975
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas.
Lacrima K; Rinaldi A; Vignati S; Martin V; Tibiletti MG; Gaidano G; Catapano CV; Bertoni F
Leuk Lymphoma; 2007 Jan; 48(1):158-67. PubMed ID: 17325859
[TBL] [Abstract][Full Text] [Related]
20. Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.
Whittaker SR; Barlow C; Martin MP; Mancusi C; Wagner S; Self A; Barrie E; Te Poele R; Sharp S; Brown N; Wilson S; Jackson W; Fischer PM; Clarke PA; Walton MI; McDonald E; Blagg J; Noble M; Garrett MD; Workman P
Mol Oncol; 2018 Mar; 12(3):287-304. PubMed ID: 29063678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
